Related Experiment Videos
Plasma C-peptide in uraemic patients
Scandinavian Journal of Clinical and Laboratory Investigation
|December 1, 1978
Summary
The kidneys are the primary site for C-peptide degradation. Studies show significantly elevated C-peptide levels in patients with renal failure, supporting this hypothesis in humans.
Area of Science:
- Nephrology
- Endocrinology
- Metabolic Research
Background:
- C-peptide is a byproduct of insulin synthesis.
- The kidney's role in C-peptide metabolism has been proposed but not definitively established in humans.
Purpose of the Study:
- To investigate the kidney as the main organ for C-peptide degradation.
- To assess C-peptide levels in relation to varying degrees of renal function.
Main Methods:
- Studied 49 subjects with creatinine clearance from 0-25 ml/min.
- Measured basal steady-state plasma C-peptide (CP) and insulin (IRI) concentrations in fasting patients.
- Compared CP levels in patients with renal failure to normal subjects and nephrectomized patients.
Main Results:
- Insulin (IRI) levels were similar to normal subjects.
- C-peptide (CP) levels were elevated in most patients with renal failure.
- Nephrectomized patients exhibited six-fold higher CP levels compared to normal subjects.
- A significant inverse correlation (r = 0.51, P < 0.001) was found between renal clearance and CP levels.
Conclusions:
- Increased CP in renal failure supports the hypothesis of kidney as the primary degradation organ.
- Markedly elevated CP in nephrectomized patients strongly supports the kidney's crucial role in C-peptide metabolism in humans.